Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 1/2 Study of SBRT With or Without GC4711 for NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04476797
Recruitment Status : Recruiting
First Posted : July 20, 2020
Last Update Posted : January 24, 2022
Information provided by (Responsible Party):
Galera Therapeutics, Inc.

Brief Summary:
GTI-4711-101 is a Phase 1-2 study of the safety of GC4711, and its potential to reduce radiation-related pulmonary injury due to SBRT for early stage large or central localized NSCLC. After an open-label, Phase 1, safety cohort of approximately 5 subjects has been completed, a randomized, double-blind, placebo-controlled Phase 2 portion will be conducted.

Condition or disease Intervention/treatment Phase
SBRT NSCLC Non-metastatic Drug: GC4711 Drug: Placebo Phase 1 Phase 2

Detailed Description:

Subjects must be referred for SBRT with large (>3cm) or central localized, node negative, non-metastatic NSCLC, and have an ECOG PS score of 0-3 to be considered for enrollment. Subjects with small peripheral lesions(≤3cm) are excluded, as the aim is to improve outcome in larger, central NSCLC carrying a higher risk of pneumonitis, as well as poorer local control. Feasibility of SBRT is judged by the treating physician. Chemotherapy given before SBRT is permitted, but subjects must be immunotherapy naive.

SBRT is planned on the (persistent) PET+ tumor location for a dose of 10-12 Gy in 5 fractions, delivered on sequential weekdays. In the Phase 1, 5 subjects will each receive GC4711 by 15-minute IV infusion, before each SBRT fraction After the Phase 1, a Phase 2, randomized, double-blind, placebo-controlled study phase will be initiated, wherein approximately 66 subjects referred for SBRT with early stage large or central localized NSCLC will be randomized in a 1:1 ratio to receive either GC4711 or placebo given intravenously (IV) before each fraction of SBRT.

All subjects will be evaluated for changes in the diffusion capacity of carbon monoxide (DLCO) and pneumonitis. All subjects will be followed for 12 months for treatment related adverse effects, disease control (Progression Free Survival (PFS), Overall Survival (OS), Distant Metastases (DM) rate and local control-(RECSIST 1.1), and quality of life (FACT-L) A Data Monitoring Committee will be established for the Phase 2 portion of the study to provide independent monitoring of safety given the blinded design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) With or Without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : October 18, 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm A Active GC4711 Drug: GC4711
15 minute IV Infusion

Placebo Comparator: Arm B Placebo Drug: Placebo
15 minute IV infusion

Primary Outcome Measures :
  1. Number of dose-limiting toxicities during treatment and within 30 days post SBRT [ Time Frame: DLT 30 days post SBRT ]
    Phase 1

  2. DLCO measured by RTOG scale 3 months after completion of SBRT compared to baseline [ Time Frame: DLCO 90 days post SBRT ]
    Phase 2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects at least 18 years of age.
  2. Ability to understand and the willingness to sign a written informed consent.
  3. Histological or biopsy proven NSCLC. For peripheral lesions, cytology and/or clear imaging-guided suspicion is accepted if histology cannot be obtained.
  4. ECOG performance status of 0-3.
  5. Large (>3cm) or centrally localized (within 2cm in all directions around the proximal bronchial tree, including ultra-central tumors, abutting the bronchial tree or trachea), node negative and non-metastatic NSCLC, judged acceptable for SBRT by the treating Investigator. Staged with FDG-PET/CT, brain CT or MRI with contrast and/or mediastinoscopy, measurable disease as defined by RECIST 1.1.
  6. Adequate end-organ function, based on routine clinical and laboratory workup:

    1. ANC >1,000 cells/µl, Platelets ≥ 75,000 cells/µl, Hemoglobin ≥ 8.0 g/dl
    2. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min
    3. Total bilirubin ≤ 1.5 x ULN (or direct bilirubin below the ULN), AST and ALT ≤ 2.5 x ULN
    4. International normalized ratio (INR) (or prothrombin time (PT)) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy, if values are within the intended therapeutic range
  7. Males and females of must agree to use effective contraception starting prior to the first day of treatment and continuing after the last dose of GC4711/Placebo for 30 days (females) and 90 days (males).

Exclusion Criteria:

  1. Subjects with confirmed nodal and/or distant disease(including brain), according standard workup by local investigator
  2. Subjects with peripheral lesions 3cm or smaller
  3. Prior treatment with immunotherapy
  4. Prior intra-thoracic radiotherapy or surgery with substantial overlap in former radiation fields as determined by the treating radiation oncologist.
  5. Subjects not recovered/controlled from prior treatment-related (chemotherapy or targeted therapy) toxicities judged by treating physician.
  6. Uncontrolled malignancy other than lung cancer that requires active treatment or is deemed by the treating physicians to be likely to affect the subject's survival duration.
  7. Subjects unable to lie down with arms up with a regular breathing pattern.
  8. History of allergic reactions attributed to compounds of similar chemical or biologic composition to GC4711.
  9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
  10. Participation in other clinical trials either to treat diagnosed lung cancer or to reduce the toxicity of therapy from participating in GC4711 clinical trial.
  11. Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure.
  12. Female subjects who are pregnant or breastfeeding.
  13. Any other conditions that, in the Investigator's opinion, might indicate the subject to be unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04476797

Layout table for location contacts
Contact: Megan Holm 484-615-2036
Contact: Jon Holmlund, MD 610-725-1500

Layout table for location information
United States, Arizona
Banner MD Anderson Cancer Center Active, not recruiting
Gilbert, Arizona, United States, 85234
United States, Colorado
Banner MD Anderson Cancer Center at NCMC Recruiting
Greeley, Colorado, United States, 80631
Contact: Laurie Gasper, MD    970-810-6690      
Principal Investigator: Laurie Gasper, MD         
United States, Georgia
IACT Health Recruiting
Columbus, Georgia, United States, 31903
Contact: Douglas Ciuba, MD    706-596-5413      
Principal Investigator: Douglas Ciuba, MD         
United States, Iowa
University of Iowa Hospitals and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Contact: Sandy Vollstedt    319-353-7143      
Principal Investigator: Bryan Allen, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: David Akhavan    913-588-6046      
Principal Investigator: David Akhavan, MD         
United States, Michigan
Henry Ford Hospital Active, not recruiting
Detroit, Michigan, United States, 48208
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Tykeytra Dale    919-668-3726      
Contact: Linda Kaltenback    919-681-6804      
Principal Investigator: Christopher Kelsey, MD         
United States, Ohio
University Hospitals Cleveland Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Tithi Biswas, MD    216-844-5336      
Principal Investigator: Tithi Biswas, MD         
United States, South Carolina
Gibbs Cancer Center & Research Institute Active, not recruiting
Spartanburg, South Carolina, United States, 29303
United States, Texas
The University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Jessica Curtin    214-645-3622      
Principal Investigator: Puneeth Iyengar, MD         
United States, Washington
Providence Regional Medical Center Recruiting
Everett, Washington, United States, 98201
Contact: William Wisbeck, MD    425-297-5500      
Principal Investigator: William Wisbeck, MD         
Cancer Care Northwest Recruiting
Spokane, Washington, United States, 99218
Contact: Robert Fairbanks, MD    509-228-1000      
Principal Investigator: Robert Fairbanks, MD         
Sponsors and Collaborators
Galera Therapeutics, Inc.
Layout table for investigator information
Study Chair: Jon Holmlund, MD Chief Medical Officer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Galera Therapeutics, Inc. Identifier: NCT04476797    
Other Study ID Numbers: GTI-4711-101
First Posted: July 20, 2020    Key Record Dates
Last Update Posted: January 24, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Galera Therapeutics, Inc.:
Early stage large or central NSCLC
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases